# Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

> **NCT04221945** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1060 (actual)

## Conditions studied

- Uterine Cervical Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo for pembrolizumab
- **DRUG:** Cisplatin
- **RADIATION:** External Beam Radiotherapy (EBRT)
- **RADIATION:** Brachytherapy

## Key facts

- **NCT ID:** NCT04221945
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-12
- **Primary completion:** 2025-01-07
- **Final completion:** 2026-01-26
- **Target enrollment:** 1060 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221945, "Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04221945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*